Other agents that interfere with immune response mechanisms and thus target neuroinflammation, such as TLR-4 inhibitors, H1-receptor agonists and glucocorticoid receptor modulators, also showed a positive outcome on motor neuron survival in ALS animal models. This evidence concerns the gene TLR4 and amyotrophic lateral sclerosis.